223 related articles for article (PubMed ID: 31403802)
1. A Multifunctional Lipid-Based Nanodevice for the Highly Specific Codelivery of Sorafenib and Midkine siRNA to Hepatic Cancer Cells.
Younis MA; Khalil IA; Abd Elwakil MM; Harashima H
Mol Pharm; 2019 Sep; 16(9):4031-4044. PubMed ID: 31403802
[TBL] [Abstract][Full Text] [Related]
2. Ultra-small lipid nanoparticles encapsulating sorafenib and midkine-siRNA selectively-eradicate sorafenib-resistant hepatocellular carcinoma in vivo.
Younis MA; Khalil IA; Elewa YHA; Kon Y; Harashima H
J Control Release; 2021 Mar; 331():335-349. PubMed ID: 33484779
[TBL] [Abstract][Full Text] [Related]
3. Development of hybrid-type modified chitosan derivative nanoparticles for the intracellular delivery of midkine-siRNA in hepatocellular carcinoma cells.
Zhong J; Huang HL; Li J; Qian FC; Li LQ; Niu PP; Dai LC
Hepatobiliary Pancreat Dis Int; 2015 Feb; 14(1):82-9. PubMed ID: 25655295
[TBL] [Abstract][Full Text] [Related]
4. Small interfering RNA targeting alpha7 nicotinic acetylcholine receptor sensitizes hepatocellular carcinoma cells to sorafenib.
Hajiasgharzadeh K; Somi MH; Mansoori B; Khaze Shahgoli V; Derakhshani A; Mokhtarzadeh A; Shanehbandi D; Baradaran B
Life Sci; 2020 Mar; 244():117332. PubMed ID: 31962133
[TBL] [Abstract][Full Text] [Related]
5. Targeted and synergistic therapy for hepatocellular carcinoma: monosaccharide modified lipid nanoparticles for the co-delivery of doxorubicin and sorafenib.
Duan W; Liu Y
Drug Des Devel Ther; 2018; 12():2149-2161. PubMed ID: 30034219
[TBL] [Abstract][Full Text] [Related]
6. Engineering of small interfering RNA-loaded lipidoid-poly(DL-lactic-co-glycolic acid) hybrid nanoparticles for highly efficient and safe gene silencing: A quality by design-based approach.
Thanki K; Zeng X; Justesen S; Tejlmann S; Falkenberg E; Van Driessche E; Mørck Nielsen H; Franzyk H; Foged C
Eur J Pharm Biopharm; 2017 Nov; 120():22-33. PubMed ID: 28756280
[TBL] [Abstract][Full Text] [Related]
7. Enhancing anti-tumor efficiency in hepatocellular carcinoma through the autophagy inhibition by miR-375/sorafenib in lipid-coated calcium carbonate nanoparticles.
Zhao P; Li M; Wang Y; Chen Y; He C; Zhang X; Yang T; Lu Y; You J; Lee RJ; Xiang G
Acta Biomater; 2018 May; 72():248-255. PubMed ID: 29555460
[TBL] [Abstract][Full Text] [Related]
8. Modulating the site-specific oral delivery of sorafenib using sugar-grafted nanoparticles for hepatocellular carcinoma treatment.
Tunki L; Kulhari H; Vadithe LN; Kuncha M; Bhargava S; Pooja D; Sistla R
Eur J Pharm Sci; 2019 Sep; 137():104978. PubMed ID: 31254645
[TBL] [Abstract][Full Text] [Related]
9. Knockout of ADAM10 enhances sorafenib antitumor activity of hepatocellular carcinoma in vitro and in vivo.
Zhang W; Liu S; Liu K; Ji B; Wang Y; Liu Y
Oncol Rep; 2014 Nov; 32(5):1913-22. PubMed ID: 25176394
[TBL] [Abstract][Full Text] [Related]
10. Codelivery of sorafenib and GPC3 siRNA with PEI-modified liposomes for hepatoma therapy.
Sun W; Wang Y; Cai M; Lin L; Chen X; Cao Z; Zhu K; Shuai X
Biomater Sci; 2017 Nov; 5(12):2468-2479. PubMed ID: 29106433
[TBL] [Abstract][Full Text] [Related]
11. Enhanced delivery of sorafenib with anti-GPC3 antibody-conjugated TPGS-b-PCL/Pluronic P123 polymeric nanoparticles for targeted therapy of hepatocellular carcinoma.
Gan H; Chen L; Sui X; Wu B; Zou S; Li A; Zhang Y; Liu X; Wang D; Cai S; Liu X; Liang Y; Tang X
Mater Sci Eng C Mater Biol Appl; 2018 Oct; 91():395-403. PubMed ID: 30033270
[TBL] [Abstract][Full Text] [Related]
12. SP94 Peptide-Functionalized PEG-PLGA Nanoparticle Loading with Cryptotanshinone for Targeting Therapy of Hepatocellular Carcinoma.
Nie X; Liu Y; Li M; Yu X; Yuan W; Huang S; Ren D; Wang Y; Wang Y
AAPS PharmSciTech; 2020 Apr; 21(4):124. PubMed ID: 32342227
[TBL] [Abstract][Full Text] [Related]
13. Targeted co-delivery of Beclin 1 siRNA and FTY720 to hepatocellular carcinoma by calcium phosphate nanoparticles for enhanced anticancer efficacy.
Wu JY; Wang ZX; Zhang G; Lu X; Qiang GH; Hu W; Ji AL; Wu JH; Jiang CP
Int J Nanomedicine; 2018; 13():1265-1280. PubMed ID: 29551896
[TBL] [Abstract][Full Text] [Related]
14. Lipid-modified cell-penetrating peptide-based self-assembly micelles for co-delivery of narciclasine and siULK1 in hepatocellular carcinoma therapy.
Wang X; Wu F; Li G; Zhang N; Song X; Zheng Y; Gong C; Han B; He G
Acta Biomater; 2018 Jul; 74():414-429. PubMed ID: 29787814
[TBL] [Abstract][Full Text] [Related]
15. Synergism of cisplatin-oleanolic acid co-loaded calcium carbonate nanoparticles on hepatocellular carcinoma cells for enhanced apoptosis and reduced hepatotoxicity.
Khan MW; Zhao P; Khan A; Raza F; Raza SM; Sarfraz M; Chen Y; Li M; Yang T; Ma X; Xiang G
Int J Nanomedicine; 2019; 14():3753-3771. PubMed ID: 31239661
[No Abstract] [Full Text] [Related]
16. Co-Administration of iRGD with Sorafenib-Loaded Iron-Based Metal-Organic Framework as a Targeted Ferroptosis Agent for Liver Cancer Therapy.
Liu X; Zhu X; Qi X; Meng X; Xu K
Int J Nanomedicine; 2021; 16():1037-1050. PubMed ID: 33603367
[TBL] [Abstract][Full Text] [Related]
17. Natural Particulates Inspired Specific-Targeted Codelivery of siRNA and Paclitaxel for Collaborative Antitumor Therapy.
Wang R; Zhao Z; Han Y; Hu S; Opoku-Damoah Y; Zhou J; Yin L; Ding Y
Mol Pharm; 2017 Sep; 14(9):2999-3012. PubMed ID: 28753317
[TBL] [Abstract][Full Text] [Related]
18. Preparation and characterization of parthenolide nanocrystals for enhancing therapeutic effects of sorafenib against advanced hepatocellular carcinoma.
Liang P; Wu H; Zhang Z; Jiang S; Lv H
Int J Pharm; 2020 Jun; 583():119375. PubMed ID: 32344021
[TBL] [Abstract][Full Text] [Related]
19. Investigation of new treatment option for hepatocellular carcinoma: a combination of sorafenib with usnic acid.
Yurdacan B; Egeli U; Guney Eskiler G; Eryilmaz IE; Cecener G; Tunca B
J Pharm Pharmacol; 2019 Jul; 71(7):1119-1132. PubMed ID: 31025377
[TBL] [Abstract][Full Text] [Related]
20. 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP)-formulated, immune-stimulatory vascular endothelial growth factor a small interfering RNA (siRNA) increases antitumoral efficacy in murine orthotopic hepatocellular carcinoma with liver fibrosis.
Kornek M; Lukacs-Kornek V; Limmer A; Raskopf E; Becker U; Klöckner M; Sauerbruch T; Schmitz V
Mol Med; 2008; 14(7-8):365-73. PubMed ID: 18392108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
